Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Transcenta Holding Limited
創勝集團醫藥有限公司
(registered by way of continuation in the Cayman Islands with limited liability)
(Stock Code: 6628)

VOLUNTARY ANNOUNCEMENT

FIRST OSTEOPOROSIS PATIENT DOSED IN PHASE 2B CLINICAL TRIAL FOR ANTI-SCLEROSTIN ANTIBODY TST002

This announcement is made by Transcenta Holding Limited (the "**Company**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update. Capitalized terms used herein but not otherwise defined shall have the same meaning ascribed thereto in the prospectus of the Company dated September 14, 2021.

The board of directors of the Company (the "**Board**") is pleased to announce that the Company has completed the enrollment and dosing of the first subject on November 23, 2026 for Phase 2b clinical trial of Blosozumab (TST002) conducted in China (Clinical Trial Registration No.: CTR20263709 in China; NCT07806331 in the United States). This important milestone marks clinical pipeline development for the Company in the field of osteoporosis.

The primary objective of the Phase 2b clinical study of Blosozumab (TST002) is to evaluate the efficacy and safety of TST002 administered once every three months for 12 months in postmenopausal women with osteoporosis and low bone mass, as well as to determine the optimal dosage to enable future pivotal trials.

In the previous Phase 1b/2a clinical trial conducted in China, 32 Chinese subjects received a single dose of Blosozumab and were followed up for 85 days. The data demonstrated positive outcomes in terms of safety, bone anabolic markers, bone resorption markers, and bone mineral density (BMD). Following a single administration of up to 1,200 mg of Blosozumab, all dose groups showed an average increase in lumbar spine BMD of 3.52% to 6.20% at Day 85, and an average increase in total hip BMD of 1.30% to 2.24%.

About Blosozumab (TST002)

Blosozumab (TST002) is a humanized monoclonal antibody with neutralizing activity against sclerostin, licensed from Eli Lilly for rights in Greater China. It features a dual mechanism of action that promotes bone formation and inhibits bone resorption, thereby increasing BMD. It is being developed for the treatment of more than 90 million osteoporosis patients in China, including postmenopausal osteoporosis, osteoporosis in men and drug induced osteoporosis.

Cautionary Statement

The Company cannot guarantee that the Company will be able to ultimately successfully develop and market TST002. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Transcenta Holding Limited
Xueming Qian
Executive Director, Chairman and Chief Executive Officer

Hong Kong, November 24, 2026

As at the date of this announcement, the Board comprises (i) Dr. Xueming Qian as executive Director, chairman and chief executive officer; (ii) Dr. Li Xu and Dr. Han Sen Xu as non-executive Directors; and (iii) Mr. Jiasong Tang, Ms. Helen Wei Chen and Prof. Genhong Cheng as independent non-executive Directors.